Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Brynne, Lena ^a   Bresell, Anders ^a   Sjögren, Niclas ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Clinical data; Data integration; Decision making; Drug development; Informatics; Knowledge management; Preclinical data; Translational medicine; Visualization

Indexed keywords

ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CONCEPTUAL FRAMEWORK; DATA PROCESSING; DECISION MAKING; DECISION SUPPORT SYSTEM; DRUG DEVELOPMENT; DRUG RESEARCH; KNOWLEDGE; KNOWLEDGE DISCOVERY; KNOWLEDGE PLOT; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEDICAL INFORMATION SYSTEM; METHODOLOGY; NOMENCLATURE; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA PROTEIN BINDING; TRANSLATIONAL RESEARCH; TREATMENT EFFECT INDEX;

ALZHEIMER DISEASE; DECISION MAKING; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; KNOWLEDGE; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84885002909     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-250     Document Type: Article

References (24)

1. Drolet BC, Lorenzi NM. Translational research: understanding the continuum from bench to bedside. Transl Res 2010, 157:1-5.
2. Gabrielsson J, Dolgos H, Gillberg P-G, Bredberg U, Benthem B, Duker G. Early integration of pharmacokinetic and dynamic reasoning is essential if lead compounds are to be developed optimally: strategic considerations. Drug DiscovToday 2009, 14:358-372.
3. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA. Can the flow of medicines be improved? fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug DiscovToday 2009, 17:419-424.
4. Visser SAG, Aurell M, Jones RDO, Schuck V, Egnell A-C, Peters S, Brynne L, Yates JWT, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U. Model based drug discovery - implementation and impact. Drug Discov Today 2013, 18:764-775. 10.1016/j.drudis.2013.05.012, 23726890.
5. D360 http://www.certara.com/products/d360.
6. Szalma S, Koka V, Khasanova T, Peraksils ED. Effective knowledge management in translational medicine. J Trans Med 2010, 8:68.
7. Napier C, Wallis R. The napiergram: a tool for visualising efficacy and safety data. J Pharm and Toxicological Methods 2010, 62(2):e12.
8. Korsan B, Dykstra K, Pullman W. Transparent trade-offs:a clinical utility index (CUI) openly evaluates a product's attributes - and chance of success. Pharmceutical Executive 2005
9. Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R. The clinical utility index as a practical multiattribute approach to drug development decisions. Clin Pharmacol Ther 2009, 86:105-108. 10.1038/clpt.2009.71, 19458614.
10. Ouellet D. Benefit-risk assessment: the use of clinical utility index. Expert Opin Drug Saf 2010, 9:289-300. 10.1517/14740330903499265, 20175698.
11. MeDRA http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf.
12. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S. Efficacy of donepezil in early-stage alzheimer disease. Arch Neurol 2004, 61:1852-1856. 10.1001/archneur.61.12.1852, 15596605.
13. Adam J, Ades AE, Aslan T, Barnett D, Brain E, Claxton K, Cookson R, Duncan F, Eccleston C, Ewings P, Feest T, Forbes A, Geddes J, Goulston J, Hands L, Haxby E, et al. Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review) - final appraisal document: national institute for health and clinical excellence. NICE Guidelines 2006, 1-63. http://www.nice.org.uk/page.aspx?o=322952.
14. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Hunter J, Williams P. Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonist, and donepezil in subjects with mild-to moderate alzheimer's disease (AD). Alzheimer's & Dementia: J Alzheimer's Association 2008, 4(4):T772-T773.
15. Birks J, Harvey RJ. Donepezil for dementia due to alzheimer's disease. Cochrane Database Syst Rev 2006, 25. CD001190.
16. Gold M, Alderton A, Zvartau-Hind M, Ritchie S, Saunders A, Craft S, Landreth G, Linnamägi U, Sawchak S. Effects of rosigltazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. The Journal of the Alzheimer's Association 2009, 5(4):86.
17. Wehling M. Translational medicine: can it really facilitate the transition of research 'from bench to bedside'?. Eur J Clin Pharmacol 2006, 62:91-95.
18. Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success?. Nat Rev Drug Discov 2009, 8:541-546. 10.1038/nrd2898, 19543224.
19. Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Trans Med 2012, 10:39-49.
20. MeSH http://www.ncbi.nlm.nih.gov/mesh.
21. Ruch P, Gobeill J, Lovis C, Geissbühler A. Automatic medical encoding with SNOMED categories. BMC Med Inform Decis Mak 2008, 8:S1-S6. 10.1186/1472-6947-8-S1-S1, 2582797, 19007438.
22. Sioutos N, de Coronado S, Haber MW, Hartel FW, Shaiu WL, Wright LW. NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information. J Biomed Inform 2007, 40:30-43. 10.1016/j.jbi.2006.02.013, 16697710.
23. Souza T, Kush R, Evans JP. Global clinical data interchange standards are here!. Drug Discov Today 2007, 12:174-181. 10.1016/j.drudis.2006.12.012, 17275739.
24. Krishna R, Schaefer HG, Bjerrum OJ. Effective integration of system biology, biomarkers, biosimulation, and modeling in streamlining drug development. J Clin Pharmacol 2007, 47:738-43. 10.1177/0091270007300746, 17463216.